Facing NASH Therapeutic Skepticism With 89bio's Rohan Palekar

The non-alcoholic steatohepatitis (NASH) therapeutics market has proven to be an 11/10 on the difficulty scale. Despite billions of big biopharma dollars invested in therapeutic development, and a few close calls, no therapeutics have yet reached the finish line. On this episode of the Business of Biotech, 89bio CEO Rohan Palekar gives us the insider's perspective on the challenges that have beset the field, from a rigorous FDA approval process to poorly designed clinical trials and a wary investor base. Palekar also expresses optimism in his explanation of how, through a focus on safety, convenience, and cutting-edge testing technology to aid patient recruitment, 89bio is positioning itself to break the tape.